Navigation Links
In Early Test, New Hepatitis C Drug Shows Promise
Date:4/21/2010

Medication offers hope for treatment with fewer side effects, experts say,,,,

WEDNESDAY, April 21 (HealthDay News) -- Researchers are reporting that a drug is showing promise in early testing as a possible new treatment for hepatitis C, a stubborn and potentially deadly liver ailment.

It's too early to tell if the drug actually works, and it will be years before it's ready to seek federal approval to be prescribed to patients. Still, the drug -- or others like it in development -- could add to the power of new drugs in the pipeline that are poised to cure many more people with hepatitis C, said Dr. Eugene R. Schiff, director of the University of Miami's Center for Liver Diseases.

The greater possibility of a cure and fewer side effects, in turn, will lead more people who think they have hepatitis C to "come out of the woodwork," said Schiff, who's familiar with the study findings. "They'll want to know if they're positive."

An estimated 4 million people in the United States have hepatitis C, but only about 1 million are thought to have been diagnosed. The disease, transmitted through infected blood, can lead to liver cancer, scarring of the liver, known as cirrhosis, and death.

Existing treatments can cure about half of the cases. As Schiff explained, people's genetic makeup has a lot to do with whether they respond to the treatment. Those with Asian heritage do better, whereas those with an African background do worse, he said.

And there's another potential problem with existing treatments. The side effects, particularly of the treatment component known as interferon, can be "pretty hard to deal with," said Nicholas A. Meanwell, a co-author of the study and a researcher with the Bristol-Myers Squibb pharmaceutical company.

The study, published online April 21 in Nature, examines an experimental drug designed to combat the hepatitis C virus. It appears to work by interfering with a protective coating around a part of the virus that's key to its ability to reproduce, Meanwell said.

In a phase 1 trial, the first of three types of studies that new drugs must go through, researchers gave doses of the drug to a small number of people.

The level of the virus in their bodies dropped significantly for several days. The main side effect was headache, Meanwell said.

At this point, it's not clear how much the drug might cost or how it would work with existing drugs. However, Meanwell said, it could become part of a combination treatment of several drugs.

Schiff, the University of Miami doctor, said other companies are pursuing similar drugs.

For now, much of the attention in the world of liver disease is on two drugs -- telaprevir and boceprevir -- that Schiff expects will become available within the next year and a half.

Combination treatments using these drugs will become the standard treatment for many people, he said, and boost cure rates into the range of 70 to 80 percent. The drugs now under development, like the one in the new study, could be added to the regimen, he said.

More information

The U.S. Centers for Disease Control and Prevention has more on hepatitis C.



SOURCES: Eugene R. Schiff, M.D., professor, medicine, and director, division of hepatology and Center for Liver Diseases, University of Miami Miller School of Medicine, Miami; Nicholas A. Meanwell, Ph.D., researcher, Bristol-Myers Squibb, Wallingford, Conn.; April 21, 2010, Nature, online


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Increased EGFR levels may be an early marker of breast cancer
2. Childhood obesity interventions must begin early, UCSF experts say
3. Childhood Obesity Interventions Must Begin Early, UCSF Experts Say
4. Case Western Reserve receives nearly $8M to help providers enable adoption of EHRs in Ohio
5. Early Detection May Prevent Preemie Vision Problems
6. 9-country study shows wide variations in how women with early breast cancer are treated
7. Yearly Chlamydia Screening May Be Ineffective for Some
8. Simple Memory Test May Detect Early Alzheimers
9. Chemicals in Beauty Products Tied to Early Puberty in Girls
10. Simple Test May Spot Early Lung Cancer
11. Childhood Cancer Survivors At Higher Odds of Early Death
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter of indulgence ... high can result in disappointment, perhaps even self-loathing. However, those who set the bar ... from PsychTests.com reveals that behind the tendency to set low expectations is ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may ... to unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To ... for healthy coping following a traumatic event. , Trauma sufferers tend to feel a ...
(Date:6/24/2016)... ... ... crisis. Her son James, eight, was out of control. Prone to extreme mood shifts and ... him, he couldn’t control his emotions,” remembers Marcy. “If there was a knife on ... say he was going to kill them. If we were driving on the freeway, ...
(Date:6/24/2016)... Fla. (PRWEB) , ... June 24, 2016 , ... Global ... Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition ... Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this year’s ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA is ... Road To Recovery® program to drive cancer patients to and from their cancer treatments. ... the highest quality of life and ongoing independence. Getting to and from medical ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Global MEMS Devices Medical Market Analysis 2016 - Forecast to ... The report contains up to date financial ... reliable analysis. Assessment of major trends with potential impact on ... dive analysis of market segmentation which comprises of sub markets, ...
(Date:6/23/2016)... Research and Markets has announced the addition of the ... offering. The current unmet ... for MedImmune to enter. The US ageing population creates a ... considerable growth for effective anti-influenza medications. The introduction of a ... development is still in its infancy. Key ...
(Date:6/23/2016)... -- , , , WHEN: , ... , , , LOCATION: , , , Online, with free ... EXPERT PANELISTS:  , , , Frost & Sullivan,s Global Vice President ... Industry Analyst, Divyaa Ravishankar and Unmesh Lal, Program Manager , ... is witnessing an exceptional era. Several new demand spaces, such as ...
Breaking Medicine Technology: